Evaluation of the combination mode and features of p38 MAPK inhibitors: construction of different pharmacophore models and molecular docking

References

• Moss M, White J, Lambert M, et al. TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today. 2001;6:417–426. doi: 10.1016/S1359-6446(01)01738-X
   PubMed Web of Science ®Google Scholar
• Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor in rheumatoid arthritis. Arthritis Rheum. 2010;38:151–160. doi: 10.1002/art.1780380202
   Google Scholar
• Zhang L, Liu R, Luan YY, et al. Tumor necrosis factor-α induced protein 8: pathophysiology, clinical significance, and regulatory mechanism. Int J Biol Sci. 2018;14:398–405. doi: 10.7150/ijbs.23268
   PubMed Web of Science ®Google Scholar
• Newton RC, Decicco CP. Cheminform abstract: therapeutic potential and strategies for inhibiting tumor necrosis factor-α. J Med Chem. 1999;42:2295–2314. doi: 10.1021/jm980541n
   PubMed Web of Science ®Google Scholar
• Durán WN. The double-edge sword of TNF-α in ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2008;295:H2221–H2222. doi: 10.1152/ajpheart.01050.2008
   PubMed Web of Science ®Google Scholar
• Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci. 1999;55:1230–1254. doi: 10.1007/s000180050369
   PubMed Web of Science ®Google Scholar
• Chen K, Li S, Chen F, et al. Regulation of the Lactobacillus strains on HMGCoA reductase gene transcription in human HepG2 cells via nuclear factor-κB. J Microbiol Biotechnol. 2016;26:402–407. doi: 10.4014/jmb.1507.07086
   PubMed Web of Science ®Google Scholar
• Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med. 2000;28:67–77. doi: 10.1097/00003246-200004001-00008
   PubMed Web of Science ®Google Scholar
• Anand R, Kothary PC, Del Monte MA. Valproic acid inhibits human retinal pigment epithelial (hRPE) cell proliferation via a P38 MAPK signaling mechanism. Adv Exp Med Biol. 2018;1074:447–455. doi: 10.1007/978-3-319-75402-4_55
   PubMed Web of Science ®Google Scholar
• Alonso G, Ambrosino C, Jones M, et al. Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength. J Biol Chem. 2000;275:40641–40648. doi: 10.1074/jbc.M007835200
   PubMedGoogle Scholar
• Ward KW, Proksch JW, Azzarano LM, et al. Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase. Xenobiotica. 2001;31:783–797. doi: 10.1080/00498250110065621
   PubMed Web of Science ®Google Scholar
• Lee JC, Votta B, Griswold DE, et al. Inhibitory effect of SK&F 86002 on monocyte IL-1 production. Agents Actions. 1989;27:280–281. doi: 10.1007/BF01972797
   PubMedGoogle Scholar
• Palladino MA, Bahjat FR, Theodorakis EA, et al. Anti-TNF-α therapies: the next generation. Nat Rev Drug Discov. 2003;2:736–746. doi: 10.1038/nrd1175
   PubMed Web of Science ®Google Scholar
• Haddad JJ. VX-745.vertexpharmaceuticals. Curr Opin Invest Drugs. 2001;2:1070–1076.
   PubMedGoogle Scholar
• Nguyen AN, Stebbins EG, Henson M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell. Res. 2006;312:1909–1923. doi: 10.1016/j.yexcr.2006.02.026
   PubMed Web of Science ®Google Scholar
• Dumas J, Sibley R, Riedl B, et al. Discovery of a new class of p38 kinase inhibitors. Bioorg Med Chem Lett. 2000;10:2047–2050. doi: 10.1016/S0960-894X(00)00270-5
   PubMed Web of Science ®Google Scholar
• Regan J, Pargellis CA, Cirillo PF, et al. The kinetics of binding to p38MAP kinase by analogues of BIRB 796. Bioorg Med Chem Lett. 2003;13:3101–3104. doi: 10.1016/S0960-894X(03)00656-5
   PubMed Web of Science ®Google Scholar
• Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000;47:185–201. doi: 10.1016/S0162-3109(00)00206-X
   PubMed Web of Science ®Google Scholar
• Sun B, Huang WX, Liu M. Evaluation of the combination mode of azoles antifungal inhibitors with CACYP51 and the influence of site-directed mutation. J Mol Graph Model. 2017;73:157–165. doi: 10.1016/j.jmgm.2017.02.009
   PubMed Web of Science ®Google Scholar
• Zhao DM, Zhao SZ, Zhao LY, et al. Discovery of biphenyl imidazole derivatives as potent antifungal agents: design, synthesis, and structure-activity relationship studies. Bioorg Med Chem. 2017;25:750–758. doi: 10.1016/j.bmc.2016.11.051
   PubMed Web of Science ®Google Scholar
• Liu M, Chen A, Wang Y, et al. Improved solubility and stability of 7-hydroxy-4-methylcoumarin at different temperatures and pH values through complexation with sulfobutyl ether-β-cyclodextrin. Food Chem. 2015;168:270–275. doi: 10.1016/j.foodchem.2014.07.061
   PubMed Web of Science ®Google Scholar
• Ayala JM, Goyal S, Liverton NJ, et al. Serum-induced monocyte differentiation and monocyte chemotaxis are regulated by the p38 MAP kinase signal transduction pathway. J Leukoc Biol. 2000;67:869–875. doi: 10.1002/jlb.67.6.869
   PubMed Web of Science ®Google Scholar
• Asano T, Yamazaki H, Kasahara C, et al. Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4, 5, 6, 7-tetrahy dropyrazolo [1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl) pyridazin-3(2H) -one (AS1940477), a potent p38 MAP kinase inhibitor. J Med Chem. 2012;55:7772–7785. doi: 10.1021/jm3008008
   PubMed Web of Science ®Google Scholar
• Henry JR, Rupert KC, Dodd JH, et al. 6-Amino-2-(4- fluorophenyl)-4-methoxy-3-(4-pyridyl)-lH- pyrrolo [2,3-b] pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. J Med Chem. 1998;41:4196–4198. doi: 10.1021/jm980497b
   PubMed Web of Science ®Google Scholar
• Selig R, Goettert M, Schattel V, et al. A frozen analogue approach to aminopyridiny limidazoles leading to novel and promising p38 MAP kinase inhibitors. J Med Chem. 2012;55:8429–8439. doi: 10.1021/jm300852w
   PubMed Web of Science ®Google Scholar
• Laufer SA, Hauser DR, Domeyer DM, et al. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme s surface-exposed front region. J Med Chem. 2008;51:4122–4149. doi: 10.1021/jm701529q
   PubMed Web of Science ®Google Scholar
• Sun B, Huang WX, Liu M, et al. Comparison and analysis of the structures and binding modes of antifungal SE and CYP51 inhibitors. J Mol Graph Model. 2017;77:1–8. doi: 10.1016/j.jmgm.2017.07.031
   PubMed Web of Science ®Google Scholar
• Zheng Y, Dong L, Liu M, et al. Effect of pH on the complexation of kaempferol-4'-glucoside with three β-cyclodextrin derivatives: isothermal titration calorimetry and spectroscopy study. J Agric Food Chem. 2014;62:244–250. doi: 10.1021/jf404320w
   PubMed Web of Science ®Google Scholar
• Sun B, Dong Y, Lei K, et al. Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors. Bioorg Med Chem. 2019;27:2427–2437. doi: 10.1016/j.bmc.2019.02.009
   PubMedGoogle Scholar
• Zhao SZ, Zhao LY, Zhang XQ, et al. Design, synthesis, and structure-activity relationship studies of benzothiazole derivatives as antifungal agents. Eur J Med Chem. 2016;123:514–522. doi: 10.1016/j.ejmech.2016.07.067
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang H, Liu M, et al. Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors. Med Chem Comm. 2018;9:1178–1187. doi: 10.1039/C8MD00230D
   Google Scholar
• Laufer SA, Wagner GK, Kotschenreuther DA, et al. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003;46:3230–3244. doi: 10.1021/jm030766k
   PubMed Web of Science ®Google Scholar
• Peifer C, Kinkel KM, Schollmeyer D, et al. From five- to six-membered rings: 3,4- diarylquinolinone as lead for novel p38MAP kinase inhibitors. J Med Chem. 2007;50:1213–1221. doi: 10.1021/jm061097o
   PubMed Web of Science ®Google Scholar
• Li F, Zhao D, Ren J, et al. 2-(2-Methylfuran- 3-carboxamido)- 3-phenylpropanoic acid, a potential CYP26A1 inhibitor to enhance all-trans retinoic acid-induced leukemia cell differentiation based on virtual screening and biological evaluation. Bioorg Med Chem. 2013;21:3256–3261. doi: 10.1016/j.bmc.2013.03.044
   PubMed Web of Science ®Google Scholar
• Namboodiri HV, Springman EB, Karpusas M, et al. Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding. Available from: https://www.rcsb.org/structure/3MPA.
   Google Scholar
• Grum-Tokars V, Minasov G, Roy S, et al. Center for Structural Genomics of Infectious Diseases (CSGID). Human p38 alpha MAP Kinase in complex with a pyridazine based inhibitor. Available from: https://www.rcsb.org/structure/4EWQ.
   Google Scholar
• Watterson DM, Grum-Tokars VL, Roy SM, et al. Development of novel in vivo chemical probes to address CNS protein kinase involvement in synaptic dysfunction. Plos One. 2013;8:e66226. doi: 10.1371/journal.pone.0066226
   PubMed Web of Science ®Google Scholar
• Yan H, Cui P, Liu CB, et al. Molecular dynamics simulation of pyrene solubilized in a sodium dodecyl sulfate micelle. Langmuir. 2012;28:4931–4938. doi: 10.1021/la300146s
   PubMed Web of Science ®Google Scholar
• Liu M, Dong L, Chen AJ, et al. Inclusion complexes of quercetin with three b-cyclodextrins derivatives at physiological pH: spectroscopic study and antioxidant activity. Spectrochim Acta A. 2013;115:854–860. doi: 10.1016/j.saa.2013.07.008
   PubMed Web of Science ®Google Scholar